Thus, converting cold tumours into “hot” tumours, alleviating the immunosuppressive tumour microenvironment, and thereby heightening sensitivity to PD-1/PD-L1 blockade remain urgent clinical challenges [19,36]. This evidence concerns the gene PDCD1 and neoplasm.